SCHEMBL6289243

SCHEMBL6289243

CC(C)(C)NC(=O)C(N)=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.37
KDM4E B2RXH2 4/20 0.36
RAB9A P51151 2/20 0.36
CYP2C9 P11712 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
IMPDH2 P12268 1/20 0.36
IMPDH1 P20839 1/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 2/20 0.34
TDP1 Q9NUW8 1/20 0.32
CYP2C19 P33261 2/20 0.32
CYP1A2 P05177 1/20 0.32
ALOX15 P16050 1/20 0.32
BLM P54132 1/20 0.32
PMP22 Q01453 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrylammonium SCHEMBL10922152 0.84 TSHR (0.33) KDM4ERAB9ACYP2C9SMN1; SMN2IMPDH2
SCHEMBL6859267 0.81 KDM4E (0.46) EPHX1KDM4ERAB9ACYP2C9MEN1
SCHEMBL24061667 0.80 TDP1 (0.30) LMNATDP1ALOX15BLMPMP22
SCHEMBL561650 0.80 ALDH1A1 (0.32) ALDH1A1LMNATDP1ALOX15BLM
SCHEMBL669001 0.79 KDM5B (0.42) EPHX1KDM4ERAB9ACYP2C9MEN1
SCHEMBL29088791 0.78 TDP1 (0.35) EPHX1KDM4ERAB9ACYP2C9MEN1
SCHEMBL21394039 0.76 RAB9A (0.38) EPHX1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL23828 0.75
SCHEMBL9500903 0.74 KDM4E (0.39) EPHX1KDM4ERAB9ACYP2C9MEN1
SCHEMBL17660396 0.74 PIK3CD (0.47) KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962791-B2 Treatment or prophylaxis of diseases caused by pilus-forming bacteria WASHINGTON UNIVERSITY (US) 2005-11-08 US claimed
US-12593845-B2 2,6-dioxo-3,6-dihydropyrimidine compound, agricultural and horticultural bactericide, nematicide, and medical and veterinary antifungal agent NIPPON SODA CO., LTD. (JP) 2026-04-07 US disclosed
US-20240317692-A1 METHOD FOR PRODUCING URACIL COMPOUND NIPPON SODA CO., LTD. (JP) 2024-09-26 US disclosed
US-20240260575-A1 AGRICULTURAL AND HORTICULTURAL FUNGICIDAL COMPOSITION NIPPON SODA CO., LTD. (JP) 2024-08-08 US disclosed
EP-4371978-A1 METHOD FOR PRODUCING URACIL COMPOUND Nippon Soda Co., Ltd. (JP) 2024-05-22 EP disclosed
US-20240114908-A1 2,6-DIOXO-3,6-DIHYDROPYRIMIDINE COMPOUND, AGRICULTURAL AND HORTICULTURAL BACTERICIDE, NEMATICIDE, AND MEDICAL AND VETERINARY ANTIFUNGAL AGENT NIPPON SODA CO., LTD. (JP) 2024-04-11 US disclosed
EP-4344545-A1 AGRICULTURAL AND HORTICULTURAL FUNGICIDAL COMPOSITION Nippon Soda Co., Ltd. (JP) 2024-04-03 EP disclosed
CN-117597332-A Process for producing uracil compound 日本曹达株式会社 2024-02-23 CN disclosed
EP-4053120-A1 2,6-DIOXO-3,6-DIHYDROPYRIMIDINE COMPOUND, AGRICULTURAL AND HORTICULTURAL BACTERICIDE, NEMATICIDE, AND MEDICAL AND VETERINARY ANTIFUNGAL AGENT Nippon Soda Co., Ltd. (JP) 2022-09-07 EP disclosed
CN-114585610-A 2, 6-dioxo-3, 6-dihydropyrimidine compound, and agricultural and horticultural bactericide, nematicide, and medical and animal antifungal agent 日本曹达株式会社 2022-06-03 CN disclosed
US-11078168-B2 Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase Phenex Discovery Verwaltungs-GmbH (DE) 2021-08-03 US disclosed
US-20190292160-A1 SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Phenex Discovery Verwaltungs-GmbH (DE) 2019-09-26 US disclosed
US-20160096834-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2016-04-07 US disclosed
US-20120295856-A1 FREDERICAMYCIN DERIVATIVES ZENTOPHARM GMBH (DE) 2012-11-22 US disclosed
US-20120295856-A1 FREDERICAMYCIN DERIVATIVES ZENTOPHARM GMBH (DE) 2012-11-22 US disclosed
US-6242245-B1 DELIGNIFICATION BY ADDING SUSPENSION OF LACCASE, OXIDANT, MEDIATOR SUCH AS VIOLURIC ACID, AND XYLANASE TO AQUEOUS SUSPENSION OF LIGNIN MATERIAL AND MIXING; MEDIATOR DOES NOT DEACTIVATE ENZYME Consortium für elektrochemische Industrie GmbH (DE) 2001-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12593845-B2 2,6-dioxo-3,6-dihydropyrimidine compound, agricultural and horticultural bactericide, nematicide, and medical and veterinary antifungal agent CASP6, GMDS, HPD EPHX1 2143/4885KDM4E 2422/4885RAB9A 3512/4885
US-20160096834-A1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF BTK, SYK, LYN EPHX1 2450/4885KDM4E 935/4885RAB9A 1796/4885
US-20240260575-A1 AGRICULTURAL AND HORTICULTURAL FUNGICIDAL COMPOSITION CYP51A1, PIK3C3, AADAC EPHX1 1422/4885KDM4E 2505/4885RAB9A 3366/4885
US-20240317692-A1 METHOD FOR PRODUCING URACIL COMPOUND UMPS, NUDT1, DPYD EPHX1 1547/4885KDM4E 2713/4885RAB9A 3467/4885
US-11078168-B2 Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase IDO1, IDO2, INMT EPHX1 886/4885KDM4E 1577/4885RAB9A 3807/4885
US-20120295856-A1 FREDERICAMYCIN DERIVATIVES NISCH, MYC, MANBA EPHX1 4481/4885KDM4E 4504/4885RAB9A 1177/4885
US-20190292160-A1 SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, INMT EPHX1 886/4885KDM4E 1577/4885RAB9A 3807/4885
US-20240114908-A1 2,6-DIOXO-3,6-DIHYDROPYRIMIDINE COMPOUND, AGRICULTURAL AND HORTICULTURAL BACTERICIDE, NEMATICIDE, AND MEDICAL AND VETERINARY ANTIFUNGAL AGENT BROX, HPD, DAXX EPHX1 932/4885KDM4E 1038/4885RAB9A 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.